European Journal of Clinical Pharmacology

, Volume 66, Issue 9, pp 929–936

Inter-country variations in anti-asthmatic drug prescriptions for children. Systematic review of studies published during the 2000–2009 period

  • Marina Bianchi
  • Antonio Clavenna
  • Maurizio Bonati
Pharmacoepidemiology and Prescription

DOI: 10.1007/s00228-010-0845-y

Cite this article as:
Bianchi, M., Clavenna, A. & Bonati, M. Eur J Clin Pharmacol (2010) 66: 929. doi:10.1007/s00228-010-0845-y



The objective of this study was to analyse inter-and intra-country quantitative and qualitative differences in anti-asthmatic prescriptions to children and adolescents.


A literature search was performed in EMBASE and MEDLINE to identify pharmaco-epidemiological studies published from January 1, 2000 to December 31, 2008 in which anti-asthmatic prescription prevalence in out-hospital children was measured. A meta-analytic weighted average and 95% confidence intervals of prescription prevalences were calculated using a random-effect(s) model. Inter- and intra-country quantitative and, where possible, qualitative prescribing patterns were compared and assessed.


Twelve studies were identified (ten from Europe, one from Canada and one from the USA), but epidemiological indicators varied widely, and only eight were suitable for meta-analysis. The data from these studies revealed inter-country quantitative differences in prescription prevalences in the overall population ≤19 years, with Italy having a prescription prevalence of 19.0%, Canada, 18.0%, USA, 14.6%, Denmark, 13.9%, Norway, 9.1% and the Netherlands, 6.2%. The overall prevalence was 13.3%. The analysis of qualitative inter-country differences revealed that, except for Italy, inhalatory short-acting β-agonists were the most prescribed, followed by inhalatory corticosteroids.


This first overall analysis of anti-asthmatic utilization studies in out-of-hospital children indicates a wide variability in anti-asthmatic prescription prevalence. It also reveals that epidemiological evaluations should be improved by using homogeneous indicators and, in order to validate the use of anti-asthmatic prescription as a proxy of disease, the diagnosis of asthma should accompany the data of prescriptions within the same population.


PharmacoepidemiologyDrug utilization studiesAnti-asthmaticsChildhood asthma



Inhaled corticosteroid


Long-acting β-agonist


Leukotriene receptor antagonist


Short-acting β-agonist


Upper respiratory tract infection

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Marina Bianchi
    • 1
  • Antonio Clavenna
    • 1
  • Maurizio Bonati
    • 1
  1. 1.Laboratory for Mother and Child Health, Department of Public HealthMario Negri Pharmacological Research InstituteMilanItaly